Dossier assessment
Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations; first-line treatment
- PD-L1 expression ≥ 50%: added benefit not proven
- PD-L1 expression < 50%: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A23-31
- Commission
- Commission awarded on 03.04.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31
Status: Commission completed
-
Addendum
Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31
Status: Commission completed
-
Dossier assessment
Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Durvalumab (gastric or gastro-oesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed